Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H26FNO2.ClH |
| Molecular Weight | 391.907 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1=CC=C(C=C1)C2(O)CCN(CCCC(=O)C3=CC=C(F)C=C3)CC2
InChI
InChIKey=RJTOSFZZYBCYTM-UHFFFAOYSA-N
InChI=1S/C22H26FNO2.ClH/c1-17-4-8-19(9-5-17)22(26)12-15-24(16-13-22)14-2-3-21(25)18-6-10-20(23)11-7-18;/h4-11,26H,2-3,12-16H2,1H3;1H
| Molecular Formula | C22H26FNO2 |
| Molecular Weight | 355.4457 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including http://www.genome.jp/dbget-bin/www_bget?D02623+D01105
Curator's Comment: Description was created based on several sources, including http://www.genome.jp/dbget-bin/www_bget?D02623+D01105
Moperone is a first-generation (typical) antipsychotic drug that belongs to the butyrophenone type approved in Japan for the treatment of schizophrenia. It has higher antagonist affinity for D2- than 5-HT2A-receptors. It also has high binding affinity for sigma receptors. It was indicated for schizophrenia, paranoid state, psychoses, epilepsy,alcohol withdrawal syndrome. It can induce extrapyramidal motor side effects, insomnia, and thirst, but it displays generally low toxicity.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL224 Sources: http://www.ncbi.nlm.nih.gov/pubmed/11561089 |
87.0 nM [EC50] | ||
Target ID: CHEMBL217 Sources: http://www.ncbi.nlm.nih.gov/pubmed/11561089 |
1.5 nM [Ki] | ||
Target ID: CHEMBL231 Sources: http://www.ncbi.nlm.nih.gov/pubmed/17403993 |
6.1 null [pIC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Luvatrene Approved UseFor the treatment of schizophrenia |
|||
Sources: http://www.ndrugs.com/?s=moperone |
Primary | Luvatrene Approved UseIndications: schizophrenia, paranoid state |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Automated on-line in-tube solid-phase microextraction coupled with HPLC/MS/MS for the determination of butyrophenone derivatives in human plasma. | 2009-06 |
|
| Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain. | 2004-11-26 |
|
| High-performance liquid chromatographic determination of fluvoxamine and fluvoxamino acid in human plasma. | 2003-06 |
Patents
Sample Use Guides
Starting dose is 0.2-0.3 mg/kg/day; then slowly increase to 0.04-0.06 mg/kg/day
Route of Administration:
Unknown
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/11561089
Curator's Comment: Monoamine receptor antagonist and inverse agonist activity of Moperone was tested in NIH-3T3 cell-based functional assay
Moperone was tested at a 3 uM concentration
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:30:35 GMT 2025
by
admin
on
Mon Mar 31 19:30:35 GMT 2025
|
| Record UNII |
2Z2633815T
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2Z2633815T
Created by
admin on Mon Mar 31 19:30:35 GMT 2025 , Edited by admin on Mon Mar 31 19:30:35 GMT 2025
|
PRIMARY | |||
|
SUB03326MIG
Created by
admin on Mon Mar 31 19:30:35 GMT 2025 , Edited by admin on Mon Mar 31 19:30:35 GMT 2025
|
PRIMARY | |||
|
100000086123
Created by
admin on Mon Mar 31 19:30:35 GMT 2025 , Edited by admin on Mon Mar 31 19:30:35 GMT 2025
|
PRIMARY | |||
|
19747
Created by
admin on Mon Mar 31 19:30:35 GMT 2025 , Edited by admin on Mon Mar 31 19:30:35 GMT 2025
|
PRIMARY | |||
|
223-392-7
Created by
admin on Mon Mar 31 19:30:35 GMT 2025 , Edited by admin on Mon Mar 31 19:30:35 GMT 2025
|
PRIMARY | |||
|
m7621
Created by
admin on Mon Mar 31 19:30:35 GMT 2025 , Edited by admin on Mon Mar 31 19:30:35 GMT 2025
|
PRIMARY | Merck Index | ||
|
C005209
Created by
admin on Mon Mar 31 19:30:35 GMT 2025 , Edited by admin on Mon Mar 31 19:30:35 GMT 2025
|
PRIMARY | |||
|
DTXSID70959531
Created by
admin on Mon Mar 31 19:30:35 GMT 2025 , Edited by admin on Mon Mar 31 19:30:35 GMT 2025
|
PRIMARY | |||
|
CHEMBL2104700
Created by
admin on Mon Mar 31 19:30:35 GMT 2025 , Edited by admin on Mon Mar 31 19:30:35 GMT 2025
|
PRIMARY | |||
|
3871-82-7
Created by
admin on Mon Mar 31 19:30:35 GMT 2025 , Edited by admin on Mon Mar 31 19:30:35 GMT 2025
|
PRIMARY | |||
|
170974
Created by
admin on Mon Mar 31 19:30:35 GMT 2025 , Edited by admin on Mon Mar 31 19:30:35 GMT 2025
|
PRIMARY |